Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Share News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 23rd Sep 2014 09:36

AVEVA: JP Morgan reduces target price from 2450p to 1825p, while leaving its overweight rating unchanged.African Minerals: Credit Suisse reduces target price from 120p to 25p, while leaving its neutral rating unchanged.Aviva: Goldman Sachs ups target price from 490p to 515p and reiterates a neutral rating.Barr (AG): Investec moves target price from 661p to 673p retaining an add rating.Clipper Logistics: Numis initiates with a target price of 170p and an add rating.Crimson Tide: WH Ireland moves from outperform to a speculative buy.Debenhams: JP Morgan lowers target price from 70p to 64p and maintains an underweight rating.Direct Line Group: Goldman Sachs ups target price from 250p to 288p and leaves its neutral rating unaltered.easyJet: Cantor Fitzgerald increases target price from 1500p to 1600p and upgrades to buy.Ferrexpo: Credit Suisse cuts target price from 160p to 140p maintaining a neutral rating.Gemfields: JP Morgan moves target price from 47p to 55p and retains a neutral rating.Go-Ahead Group: Deutsche Bank raises target price from 2270p to 2790p and upgrades from hold to buy.Hoghland Gold Mining: Westhouse Securities upgrades from add to buy with a target price of 80p.Legal & General: Goldman Sachs ups target price from 220p to 235p and maintains a neutral rating.London Mining: Credit Suisse cuts target price from 100p to 80p and reiterates an outperform rating.Monitise: UBS initiates with a target price of 80p and a buy recommendation.Old Mutual: Goldman Sachs shifts target price from 215p to 222p and keeps a buy recommendation.Playtech: Nomura raises target price from 753p to 830p and stays with its buy recommendation.Prudential: Goldman Sachs ups target price from 1580p to 1630p maintaining a buy recommendation.PZ Cussons: Panmure Gordon downgrades to hold with a target price of 410p.Regenersis: Panmure Gordon cuts target price from 502p to 403p and maintains its buy recommendation.Serco Group: Liberum Capital reduces target price from 350p to 300p maintaining a hold recommendation.Smiths Group: Deutsche Bank cuts target price from 1350p to 1300p, while staying with its hold recommendation. UBS lowers target price from 1170p to 1165p reiterating its sell recommendation.Skyepharma: Oriel Securities initiates with a target price of 460p and a buy recommendation.Standard Life: Goldman Sachs raises target price from 375p to 405p and keeps a neutral rating.Tesco: JP Morgan cuts target price from 210p to 185p keeping an underweight rating. Nomura lowers target price from 220p to 200p, while its neutral rating remains unchanged. Deutsche Bank reduces target price from 250p to 220p and maintains a hold recommendation.Thomas Cook Group: Goldman Sachs increases target price from 90p to 140p and keeps a neutral rating.Wilmington Group: N+1 Singer ups target price from 220p to 250p upgrading to buy.
More News
10 Jun 2016 06:56

Vectura-Skyepharma Merger Completed As Scheme Becomes Effective (ALLISS)

Read more
7 Jun 2016 14:02

Skyepharma To Develop Product For US Opioid Market

Read more
26 May 2016 06:56

Vectura Sees Narrowed Loss Ahead Of Skyepharma Deal Completion

Read more
20 May 2016 06:29

Vectura Says Skyepharma Deal To Complete By June 10

Read more
18 May 2016 07:24

Skyepharma Says Trading Good, Anticipates Full-Year Revenue Growth

Read more
16 May 2016 16:13

Vectura, Skyepharma Merger Cleared By UK Competition Authority

Read more
11 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
30 Mar 2016 06:53

Skyepharma Says Flutiform Version Accepted For Europe Review

Read more
17 Mar 2016 11:52

Vectura receives support from Skyepharma shareholder

(ShareCast News) - Vectura - which focuses on the development of pharmaceutical therapies for airways diseases - has received a letter of intent from a Skyepharma shareholder supporting the companies' proposed merger. Vectura said River and Mercantile Asset Management, which owns just under 4.8m Sky

Read more
17 Mar 2016 11:15

Vectura Gets Support From Skyepharma Shareholder For Takeover (ALLISS)

Read more
16 Mar 2016 12:26

UPDATE 1-Vectura to buy SkyePharma for $620 mln as UK biotech consolidates

* Agreed offer values SkyePharma at 410.15 pence a share * Combined group market value more than 1 billion pounds (Adds more on rationale for deal, comment from CEO) By Ben Hirschler LONDON, March 16 (Reuters) - Respiratory drug specialist Vectura has agreed to buy rival SkyeP

Read more
16 Mar 2016 09:06

Skyepharma Agrees To Merge With Vectura As It Swings To Profit (ALLISS)

Read more
16 Mar 2016 08:55

Skyepharma and Vectura agree merger; Skyepharma swings to profit

(ShareCast News) - Vectura and Skyepharma have reached an agreement on the terms of a recommended merger. Under the terms of the deal, Skyepharma shareholders will get 2.7977 new Vectura shares for each Skyepharma share. Based on Vectura's closing price of 146.60p on Tuesday, this values Skyepharma

Read more
9 Mar 2016 16:12

Earnings, Trading Statements Calendar - Week Ahead

Read more
2 Feb 2016 11:00

CORRECT (Jan 28): Skyepharma Signs Flutiform Deal With Mundipharma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.